Physician profile
Jonathan James Corbett
NPI 1174919948
$4,713.19
in general payments reported to CMS, 2019-2025
31 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $338 · 2021: $239 · 2022: $372 · 2023: $412 · 2024: $1,941 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,858 · Travel and Lodging: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,857.80 |
| Travel and Lodging | $686.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $869.86 | 2024 | Aquabeam System |
| Dendreon Pharmaceuticals LLC | $571.28 | 2020-2025 | Provenge |
| Boston Scientific Corporation | $411.57 | 2019-2025 | Lithovue |
| Urogen Pharma, INC. | $291.47 | 2022-2025 | Jelmyto |
| Abbvie INC. | $236.12 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $229.10 | 2023-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $201.51 | 2023-2025 | Erleada, Akeega, Balversa |
| Teleflex LLC | $172.71 | 2021-2025 | Barrigel |
| Medtronic, INC. | $170.76 | 2025 | Interstim, Altaviva |
| Merck Sharp & Dohme LLC | $168.67 | 2024-2025 | Keytruda, Lynparza |
| Pfizer INC. | $150.84 | 2021-2025 | |
| Blue Earth Diagnostics | $139.97 | 2021-2022 | |
| Astellas Pharma US INC | $137.87 | 2021-2024 | Xtandi |
| Stryker Corporation | $101.28 | 2020 | |
| Immunitybio, INC. | $97.50 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $97.42 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.91 | 2023-2024 | |
| Endo Pharmaceuticals INC. | $85.79 | 2021-2023 | Aveed, Xiaflex |
| Myovant Sciences INC. | $70.01 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $64.98 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $56.68 | 2024-2025 | Lynparza, Imfinzi |
| Tolmar Pharmaceuticals, INC. | $52.79 | 2021 | |
| Olympus America INC. | $50.61 | 2025 | Itind System |
| Endo USA, INC. | $47.07 | 2025 | Xiaflex, Aveed |
| Laborie Medical Technologies Corp. | $34.01 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $28.23 | 2025 | |
| Sun Pharmaceutical Industries INC. | $26.40 | 2025 | |
| Clarus Therapeutics INC. | $17.37 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.66 | 2023 | Seglentis |
| Verity Pharmaceuticals INC. | $15.19 | 2024 | Trelstar |
| Tolmar, INC. | $13.56 | 2025 | Jatenzo, Eligard |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Corbett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.